{"id":7592,"date":"2024-09-22T19:30:25","date_gmt":"2024-09-22T17:30:25","guid":{"rendered":"https:\/\/smc-news.ch\/?p=7592"},"modified":"2024-09-23T11:56:39","modified_gmt":"2024-09-23T09:56:39","slug":"nouveaux-developpements-dans-le-domaine-des-therapies-anti-amyloides","status":"publish","type":"post","link":"https:\/\/smc-news.ch\/fr\/nouveaux-developpements-dans-le-domaine-des-therapies-anti-amyloides\/","title":{"rendered":"Nouveaux d\u00e9veloppements dans le domaine des th\u00e9rapies anti-amylo\u00efdes"},"content":{"rendered":"\n<p><strong>Quelles autorit\u00e9s d&rsquo;agr\u00e9ment d\u00e9cident et comment : un bref aper\u00e7u<\/strong><\/p>\n\n<p>Le 25 juillet 2024, l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) a d\u00e9cid\u00e9 de ne pas accorder d&rsquo;autorisation de mise sur le march\u00e9 au Leqembi\u00ae(lecanemab), un anticorps anti-amylo\u00efde, contrairement aux agences des m\u00e9dicaments des \u00c9tats-Unis, du Japon, de la Chine, de Hong Kong, de la Cor\u00e9e du Sud et d&rsquo;Isra\u00ebl. Cette d\u00e9cision a \u00e9t\u00e9 motiv\u00e9e par un rapport b\u00e9n\u00e9fice\/risque insuffisant. La proc\u00e9dure de recours est en cours.  <\/p>\n\n<p>Le 22.8.2024, l&rsquo;agence britannique de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) a autoris\u00e9 le Leqembi\u00ae (lecanemab). L&rsquo;\u00e9valuation par le NICE (National Institute for Health and Care Excellence) concernant l&rsquo;utilisation clinique dans le syst\u00e8me de sant\u00e9 national n&rsquo;est pas encore termin\u00e9e. <\/p>\n\n<p>Une d\u00e9cision de Swissmedic est attendue avant la fin de l&rsquo;ann\u00e9e. En outre, des d\u00e9cisions de l&rsquo;EMA et de Swissmedic sont \u00e9galement attendues concernant l&rsquo;autorisation du Kisunla\u00ae (donanemab). Le Kisunla\u00ae a re\u00e7u l&rsquo;autorisation de la FDA (USA) le 02.07.2024.  <\/p>\n\n<p><\/p>\n\n<p>Plus d&rsquo;informations avec les liens suivants :<\/p>\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi\" target=\"_blank\" rel=\"noreferrer noopener\">Leqembi | Agence europ\u00e9enne des m\u00e9dicaments (EMA)<\/a><\/div>\n<\/div>\n\n<p class=\"has-white-color has-text-color has-link-color wp-elements-7e4ac651328708ea719ac0894fa30934\">.<\/p>\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.alzheimer-schweiz.ch\/fr\/medias\/article\/lema-soppose-a-la-mise-sur-le-marche-du-lecanemab\" target=\"_blank\" rel=\"noreferrer noopener\">L\u2019EMA s\u2019oppose \u00e0 la mise sur le march\u00e9 du lecanemab<\/a><\/div>\n<\/div>\n\n<p class=\"has-white-color has-text-color has-link-color wp-elements-7e4ac651328708ea719ac0894fa30934\">.<\/p>\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.gov.uk\/government\/organisations\/medicines-and-healthcare-products-regulatory-agency\" target=\"_blank\" rel=\"noreferrer noopener\">Medicines and Healthcare products Regulatory Agency &#8211; GOV.UK<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Quelles autorit\u00e9s d&rsquo;agr\u00e9ment d\u00e9cident et comment : un bref aper\u00e7u Le 25 juillet 2024, l&rsquo;Agence europ\u00e9enne des m\u00e9dicaments (EMA) a d\u00e9cid\u00e9 de ne pas accorder d&rsquo;autorisation de mise sur le march\u00e9 au Leqembi\u00ae(lecanemab), un anticorps anti-amylo\u00efde, contrairement aux agences des m\u00e9dicaments des \u00c9tats-Unis, du Japon, de la Chine, de Hong Kong, de la Cor\u00e9e du [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6769,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[27],"tags":[],"class_list":["post-7592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recherche"],"_links":{"self":[{"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/posts\/7592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/comments?post=7592"}],"version-history":[{"count":3,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/posts\/7592\/revisions"}],"predecessor-version":[{"id":7648,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/posts\/7592\/revisions\/7648"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/media\/6769"}],"wp:attachment":[{"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/media?parent=7592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/categories?post=7592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smc-news.ch\/fr\/wp-json\/wp\/v2\/tags?post=7592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}